-
-
-
-
-
-
-
Pfizer Q2 earnings preview: Analysts eye pipeline updates, portfolio resilience
-
-
-
-
-
-
-
FDA approves Padcev plus Keytruda for muscle-invasive bladder cancer
-
-
-
-
-
-
-
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
-
-
-
-
-
-
-
FDA approves expanded HYMPAVZI use for hemophilia patients with inhibitors
-
-
-
-
-
-
-
Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
-
-
-
-
-
-
-
Pfizer starts phase 3 trial for pediatric pneumococcal vaccine
-
-
-
-
-
-
-
Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance
-
1,221,966 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

